Serum Urate During Acute Gout

2009 ◽  
Vol 36 (6) ◽  
pp. 1287-1289 ◽  
Author(s):  
NAOMI SCHLESINGER ◽  
JOSEPHINE M. NORQUIST ◽  
DOUGLAS J. WATSON
Keyword(s):  
Uric Acid ◽  
Serum Urate ◽  
Acute Attack ◽  
Normal Serum ◽  
The Body ◽  
Acute Gout ◽  
Acid Pool ◽  
Randomized Controlled Clinical Trials ◽  
Acute Gout Treatment ◽  
The Relationship

Objective.To study the frequency of normal serum urate (SU) levels during acute gout in the largest studies of acute gout treatment to date.Methods.Data collected from 2 randomized controlled clinical trials assessing the efficacy of etoricoxib or indomethacin for 7 days in acute gout were used to assess SU levels during acute gouty attacks. Efficacy was similar with both agents, so both groups were combined for analysis.Results.A total of 339 patients were enrolled in the 2 studies; 94% were male; mean age was 50.5 years. At baseline, 14% of patients had a “true” normal SU (≤ 6 mg/dl) and 32% had SU ≤ 8 mg/dl during acute gout. Baseline mean SU was 7.1 versus 8.5 mg/dl (p < 0.001) in those taking allopurinol versus nonusers. Patients taking chronic allopurinol were more likely to have lower SU at baseline compared to those not taking chronic allopurinol (p < 0.001) during the acute attack.Conclusion.A normal SU level at presentation does not exclude an acute gouty attack. In the largest studies of acute gout to date, attacks still occurred despite SU levels being below 6.8 mg/dl, the saturation level for urate. This may be attributed to persistence of tophi and an increased body uric acid pool. Additional studies are needed to determine the correlation between SU and the body uric acid pool as well as the relationship to timing of changes during acute gout.

scholarly journals PERBANDINGAN KADAR ASAM URAT PADA SUBYEK OBES DAN NON-OBES DI FAKULTAS KEDOKTERAN UNIVERSITAS SAM RATULANGI MANADO

e-CliniC ◽  
2015 ◽  
Vol 3 (2) ◽  
Author(s):  
Elim Rau ◽  
Jeffrey Ongkowijaya ◽  
Ventje Kawengian
Keyword(s):  
Uric Acid ◽  
Body Fat ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Normal Serum ◽  
The Body ◽  
Obese Group ◽  
Male Students ◽  
Cross Sectional

Abstract: Uric acid is the end product of purine metabolism. Circulating uric acid in the human body is produced by the body (endogenous uric acid) as well as derived from food (exogenous uric acid). Normal serum uric acid level is <7.0 mg / dL in men and <6.0 in women. Obesity can be defined as excess body fat. One of the markers used for body fat content is body mass index (BMI). This study aimed to compare the levels of uric acid in obese and non-obese subjects. This was an analytical study with a cross sectional design. The population is students of Faculty of Medicine University of Sam Ratulangi Manado. Samples were male students of batch 2013. There were 42 male students, consisted of 21 obese and 21 non-obese students. The results showed that the average of uric acid levels in obese group was 8.05 mg/dL and in non-obese group 6.63 mg/dL. In the obese group, 67% had an increase in uric acid level meanwhile in the non-obese group only 38%. The statistical test showed a sig 0,009. Conclusion: In this study, the average of uric acid level in obese group was significantly higher than in the non-obese group. However, there were students with either normal or high uric acid levels in both groups.Keywords: uric acid, obeseAbstrak: Asam urat merupakan produk akhir metabolisme purin. Asam urat yang beredar di dalam tubuh manusia di produksi sendiri oleh tubuh (asam urat endogen) dan berasal dari makanan (asam urat eksogen). Normalnya kadar asam urat serum <7,0 mg/dL pada pria dan <6,0 mg/dL pada wanita. Obesitas dapat di definisikan sebagai kelebihan lemak tubuh. Penanda kandungan lemak tubuh yang digunakan ialah indeks masa tubuh (IMT). Penelitian ini bertujuan untuk mengetahui perbandingan kadar asam urat pada subyek obes dan non obes. Penelitian ini bersifat analitik dengan pendekatan potong lintang. Populasi penelitian ialah mahasiswa Fakultas Kedokteran Universitas Sam Ratulangi Manado. Sampel idalah mahasiswa pria angkatan 2013 dan didapatkan 42 orang yang terbagi atas 21 obes dan 21 non obes. Hasil penelitian memperlihatkan rerata kadar asam urat pada obes 8,05 mg/dL dan pada non-obes 6,63 mg/dL. Peningkatan kadar asam urat ditemukan 67% pada kelompok obes dan 38% pada kelompok non-obes. Uji statistik menunjukkan nilai sig 0,009. Simpulan: Pada penelitian ini rerata kadar asam urat pada kelompok obes lebih tinggi secara bermakna daripada kelompok non-obes. Walaupun demikian, pada kedua kelompok ditemukan mahasiswa dengan kadar asam urat normal maupun meningkat.Kata kunci: asam urat, obesitas

Gout

2013 ◽  
pp. 1199-1210
Author(s):  
Nicola Dalbeth
Keyword(s):  
Disease Patient ◽  
Joint Damage ◽  
Serum Urate ◽  
Acute Attack ◽  
Dietary Factors ◽  
Acute Gout ◽  
Chronic Synovitis ◽  
Renal Tubular

Gout is a common and treatable disorder of purine metabolism. Gout typically presents as recurrent self-limiting episodes of severe inflammatory arthritis affecting the foot. In the presence of persistent hyperuricaemia, tophi, chronic synovitis, and joint damage may develop. Diagnosis of gout is confirmed by identification of monosodium urate (MSU) crystals using polarizing light microscopy. Hyperuricaemia is the central biochemical cause of gout. Genetic variants in certain renal tubular urate transporters including SLC2A9 and ABCG2, and dietary factors including intake of high-purine meats and seafood, beer, and fructose, contribute to development of hyperuricaemia and gout. Gout treatment includes: (1) management of the acute attack using non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or low-dose colchicine; (2) prophylaxis against gout attacks when commencing urate-lowering therapy (ULT), with NSAIDs or colchicine; and (3) long-term ULT to achieve a target serum urate of less than 0.36 mmol/litre. Interleukin (IL)-1β‎‎ is a central mediator of acute gouty inflammation and anti-IL-1β‎‎ therapies show promise for treatment of acute attacks and prophylaxis. The mainstay of ULT remains allopurinol. However, old ULT agents such as probenecid and benzbromarone and newer agents such as febuxostat and pegloticase are also effective, and should be considered in patients in whom allopurinol is ineffective or poorly tolerated. Management of gout should be considered in the context of medical conditions that frequently coexist with gout, including type 2 diabetes, hypertension, dyslipidaemia, and chronic kidney disease. Patient education is essential to ensure that acute gout attacks are promptly and safely managed, and long-term ULT is maintained.

scholarly journals Sex-Specific Association of Uric Acid and Kidney Function Decline in Taiwan

2021 ◽  
Vol 11 (5) ◽  
pp. 415
Author(s):  
Po-Ya Chang ◽  
Yu-Wei Chang ◽  
Yuh-Feng Lin ◽  
Hueng-Chuen Fan
Keyword(s):  
Uric Acid ◽  
Kidney Disease ◽  
Elevated Serum ◽  
Serum Urate ◽  
Renal Progression ◽  
Function Management ◽  
Incidence Of Ckd ◽  
Specific Association ◽  
Kidney Function Decline ◽  
The Relationship

An elevated serum urate concentration is associated with kidney damage. Men’s uric acid levels are usually higher than women’s. However, postmenopausal women have a higher risk of gout than men, and comorbidities are also higher than in men. This study examined the sex differences in the relationship between hyperuricemia and renal progression in early chronic kidney disease (CKD) and non-CKD, and further examined the incidence of CKD in non-CKD populations among patients over 50 years of age. We analyzed 1856 women and 1852 men participating in the epidemiology and risk factors surveillance of the CKD database. Women showed a significantly higher risk of renal progression and CKD than men within the hyperuricemia group. After adjusting covariates, women, but not men resulted in an hazard ratio (HR) for developing renal progression (HR = 1.12; 95% CI 1.01–1.24 in women and HR = 1.03; 95% CI 0.93–1.13 in men) and CKD (HR = 1.11; 95% CI 1.01–1.22 in women and HR = 0.95; 95% CI 0.85–1.05 in men) for each 1 mg/dL increase in serum urate levels. The association between serum urate levels and renal progression was stronger in women. Given the prevalence and impact of kidney disease, factors that impede optimal renal function management in women and men must be identified to provide tailored treatment recommendations.

scholarly journals Vitamin D3 Level And Risk of Diabetes In Patients With Hyperuricemia

2021 ◽  
Author(s):  
Gong Rongpeng ◽  
Zixin Xu ◽  
Xiaoxin Wei
Keyword(s):  
Uric Acid ◽  
Vitamin D3 ◽  
Multivariate Logistic Regression Analysis ◽  
Cross Sectional Study ◽  
The Body ◽  
Sufficient Evidence ◽  
Cross Sectional ◽  
Factors Affecting ◽  
The Difference ◽  
The Relationship

Abstract BackgroundPrevious studies have shown that hyperuricemia is involved in diabetes, obesity, hypertension, chronic kidney disease, and other diseases. At the same time, studies have shown that vitamin D3 levels in the body are linked to the onset of diabete. However, there is currently no sufficient evidence to prove whether this connection is affected by uric acid levels. Therefore, we attempted to investigate the relationship between vitamin D3 content and the occurrence of diabetes in the hyperuricemia population by using the data of the NHANES database from 2009 to 2018.MethodWe conducted a cross-sectional study using the NHANES database. According to strict inclusion and exclusion criteria, we finally selected 3543 representative data. Multivariate logistic regression analysis was used to explore the relationship between vitamin D3 and diabetes in the hyperuricemia population after complete adjustment. We found a linear relationship between vitamin D3 content and the incidence of diabetes.ResultThe results of this study showed that there was a correlation between the content of vitamin D3 and the incidence of diabetes in people with hyperuricemia, and the effect values (OR and 95% confidence interval) were 0.95and (0.92-0.98), respectively, and the difference was statistically significant.ConclusionOur study shows that vitamin D3 content is associated with the incidence of diabetes in people with high uric acid. This study provides a new idea for exploring the factors affecting the pathogenesis of diabetes in patients with hyperuricemia.

scholarly journals Pharmacotherapy for gout

2021 ◽  
Vol 64 (11) ◽  
pp. 772-777
Author(s):  
Chang-Nam Son
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Serum Urate ◽  
Treat To Target ◽  
Common Disease ◽  
Uric Acid Concentration ◽  
Acute Gout ◽  
Serum Uric Acid Concentration ◽  
Inflammatory Drugs

Background: Gout is a common disease that is mainly caused by hyperuricemia. Although it is relatively easy to treat, adherence to drug treatment and the rate at which treatment targets are met is low.Current Concepts: For the treatment of acute gout attack, colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids can be used alone or in combination depending on the severity of symptoms. To prevent gout attacks, patients are started on colchicine prior to or concurrent with treatment with uric acid–lowering drugs. The treatment is maintained until serum uric acid levels have returned to normal, and the patient has had no acute attacks for three to six months. Ultimately, the symptoms of gout are controlled in the long term by treating the patient’s hyperuricemia. For this purpose, allopurinol, febuxostat, and benzbromarone are used, and the side effects and contraindications for each drug should be checked. The goal for the treatment of chronic gout is to maintain a serum uric acid concentration below 6.0 mg/dL.Discussion and Conclusion: Patients visit the emergency departments of hospitals for sudden gout attacks. However, gout is a chronic disease that requires the lifelong use of uric acid–lowering agents. Therefore, it is necessary to educate patients on a serum urate-based treat-to-target approach.

scholarly journals Level of Salivary Uric Acid in Gingivitis and Periodontitis Patients

2017 ◽  
Vol 1 (1) ◽  
pp. 7 ◽  
Author(s):  
Muhammad Ihsan Rizal ◽  
Stiefani Vega
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
The Body ◽  
Probing Depth ◽  
Dental Hospital ◽  
Antioxidant Agent ◽  
Antioxidant Enzymes Activities ◽  
Wu Method ◽  
The Relationship

<p><strong>Background:</strong> Periodontal disease is common chronic adult condition. Antioxidants are present in the body fluid as protection against free radical. Uric acid is one of antioxidants that can be found in saliva. Moreover, the relationship among the antioxidant enzymes activities and clinical periodontal status were investigated. <strong>Objectives:</strong> The aim of the study was to observe uric acid level activities in the saliva of gingivitis and periodontitis patients. <strong>Methods:</strong> Six patients with gingivitis and six patients with periodontitis in Dental Hospital Trisakti University were included in the study. Clinical condition of each subject, the plaque index, and probing depth were determined. The salivary uric acid level was measured using the Folin-Wu method. <strong>Result:</strong> Salivary uric acid levels in the periodontitis patients with a mean ± SD  7.40 ± 0.31  (p = 0.004) were found to be higher compared to the gingivitis patients (mean ± SD = 6.84 ± 0.19). In addition, there were no significant differences in salivary uric acid levels between gender (p = 0.641). <strong>Conclusion:</strong> Uric acid levels in periodontitis patients were found to be higher than in gingivitis patients. Moreover, uric acid has more role on periodontitis than in gingivitis as an antioxidant agent.</p>

Gout

2016 ◽  
Author(s):  
Nicola Dalbeth
Keyword(s):  
Disease Patient ◽  
Joint Damage ◽  
Serum Urate ◽  
Acute Attack ◽  
Dietary Factors ◽  
Acute Gout ◽  
Chronic Synovitis ◽  
Inflammatory Drugs ◽  
Renal Tubular

Gout is a common and treatable disorder of purine metabolism. Gout typically presents as recurrent self-limiting episodes of severe inflammatory arthritis affecting the foot. In the presence of persistent hyperuricaemia, tophi, chronic synovitis, and joint damage may develop. Diagnosis of gout is confirmed by identification of monosodium urate (MSU) crystals using polarizing light microscopy. Hyperuricaemia is the central biochemical cause of gout. Genetic variants in certain renal tubular urate transporters including SLC2A9 and ABCG2, and dietary factors including intake of high-purine meats and seafood, beer, and fructose, contribute to development of hyperuricaemia and gout. Gout treatment includes: (1) management of the acute attack using non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or low-dose colchicine; (2) prophylaxis against gout attacks when commencing urate-lowering therapy (ULT), with NSAIDs or colchicine; and (3) long-term ULT to achieve a target serum urate of less than 0.36 mmol/litre. Interleukin (IL)-1β‎ is a central mediator of acute gouty inflammation and anti-IL-1β‎ therapies show promise for treatment of acute attacks and prophylaxis. The mainstay of ULT remains allopurinol. However, old ULT agents such as probenecid and benzbromarone and newer agents such as febuxostat and pegloticase are also effective, and should be considered in patients in whom allopurinol is ineffective or poorly tolerated. Management of gout should be considered in the context of medical conditions that frequently coexist with gout, including type 2 diabetes, hypertension, dyslipidaemia, and chronic kidney disease. Patient education is essential to ensure that acute gout attacks are promptly and safely managed, and long-term ULT is maintained.

Gout

2013 ◽  
Author(s):  
Nicola Dalbeth
Keyword(s):  
Disease Patient ◽  
Joint Damage ◽  
Serum Urate ◽  
Acute Attack ◽  
Dietary Factors ◽  
Acute Gout ◽  
Chronic Synovitis ◽  
Inflammatory Drugs ◽  
Renal Tubular

Gout is a common and treatable disorder of purine metabolism. Gout typically presents as recurrent self-limiting episodes of severe inflammatory arthritis affecting the foot. In the presence of persistent hyperuricaemia, tophi, chronic synovitis, and joint damage may develop. Diagnosis of gout is confirmed by identification of monosodium urate (MSU) crystals using polarizing light microscopy. Hyperuricaemia is the central biochemical cause of gout. Genetic variants in certain renal tubular urate transporters including SLC2A9 and ABCG2, and dietary factors including intake of high-purine meats and seafood, beer, and fructose, contribute to development of hyperuricaemia and gout. Gout treatment includes: (1) management of the acute attack using non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or low-dose colchicine; (2) prophylaxis against gout attacks when commencing urate-lowering therapy (ULT), with NSAIDs or colchicine; and (3) long-term ULT to achieve a target serum urate of less than 0.36 mmol/litre. Interleukin (IL)-1β‎ is a central mediator of acute gouty inflammation and anti-IL-1β‎ therapies show promise for treatment of acute attacks and prophylaxis. The mainstay of ULT remains allopurinol. However, old ULT agents such as probenecid and benzbromarone and newer agents such as febuxostat and pegloticase are also effective, and should be considered in patients in whom allopurinol is ineffective or poorly tolerated. Management of gout should be considered in the context of medical conditions that frequently coexist with gout, including type 2 diabetes, hypertension, dyslipidaemia, and chronic kidney disease. Patient education is essential to ensure that acute gout attacks are promptly and safely managed, and long-term ULT is maintained.

scholarly journals Hyperuricaemia and gout

2020 ◽  
pp. 95-100
Author(s):  
A Kopke ◽  
OBW Greeff
Keyword(s):  
Uric Acid ◽  
Side Effects ◽  
Treatment Options ◽  
The Body ◽  
Acute Gout ◽  
Tophaceous Gout ◽  
Life Threatening ◽  
Inflammatory Drugs ◽  
Urate Crystals

Gout is a painful, inflammatory disease that affects more men than women. The incidence of gout has increased substantially over the past few decades, as evidenced by information from the Rochester project. Some of the risk factors for the development of gout include: increased ethanol intake, high dietary purine consumption, obesity and the use of certain drugs, such as diuretics. Another important risk factor for the development of gout is hyperuricaemia. Hyperuricaemia results from an imbalance between the rate of production and excretion of uric acid in the body. An excess of uric acid thus builds up in the body, supersaturating body fluids and leading to the formation of monosodium urate crystals. These crystals accumulate in tissue and around joints, leading to an acute gout attack. Gout can be divided into four phases, namely asymptomatic hyperuricaemia, acute gout attacks or recurrent gout, intercritical gout and chronic tophaceous gout. Various treatment options are available for gout, and the treatment for each gout patient is determined by the stage of the disease. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, corticotropin and colchicine are used for the treatment of acute gout attacks. Allopurinol and probenecid are used for long-term hypouricaemic therapy, while NSAIDs and colchicine are prescribed for the prophylaxis of future gout attacks. All of these treatments have side-effects, ranging from mild to life-threatening in nature. There is a need for novel gout therapies that have fewer side-effects but are still as effective.

Sign in / Sign up

Export Citation Format

Share Document